Investor Conference Call

Q2 2020 Results


Investor News August 04, 2020

Second quarter of 2020:

Bayer: Solid performance despite COVID-19 impact

Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations - agreements in major legacy Monsanto litigation / Core earnings per share increase by 5.3 percent to 1.59 euros / Free cash flow rises to 1.402 billion euros / Outlook adjusted for COVID-19 impact MORE

Investor Conference Call

Tuesday, August 4, 2020
Start at approx. 2:00 p.m. CEST (12:00 noon UTC)



Werner Baumann
CEO of
Bayer AG

Audio recording of the investor conference call (including slides)


Audio file

You can also play the audio recording on your mobile device.


Presentation charts

Half-Year Report 2020


Wolfgang Nickl
CFO of
Bayer AG


Q2 2020 All in One Package for Investors and Analysts